Case Reports in Medicine

Case Reports in Medicine / 2011 / Article

Case Report | Open Access

Volume 2011 |Article ID 897167 | 4 pages | https://doi.org/10.1155/2011/897167

Mobile Right Atrial Thrombi in a Patient with the Hemoglobin SC Disease

Academic Editor: William J. Brady
Received23 Jun 2011
Accepted07 Jul 2011
Published06 Sep 2011

Abstract

The formation of Intracardiac thrombi is rare in the absence of structural heart disease or atrial fibrillation. We describe a case of spontaneous right atrial thrombus formation that occurred in a patient with a hypercoagulable condition who had been sub optimally anticoagulated.

1. Introduction

Sickle cell disease (SCD) is an inherited autosomal recessive disorder characterized by the formation of haemoglobin S (HbS) resulting from the amino acid substitution of glutamate to valine on the beta chain of haemoglobin. The vasoocclusive and haemolytic complications of this disease are well known however it is worth noting that there are clinical manifestations of this hypercoagulable disease such as large vessel thrombosis, and in rare cases, intracardiac thrombus.

We report a case of spontaneous right atrial thrombus formation in a patient with sickle cell disease who had been suboptimally anticoagulated.

2. Case Report

A 52-year-old man with haemoglobin SC disease, a previous surgical splenectomy 26 years prior, following a crisis, and pulmonary arterial hypertension secondary to chronic thromboembolic disease, presented with acute dyspnoea and pleuritic chest pain. Four days earlier, he had run out of warfarin and had neglected to renew his prescription. His admission ECG showed anterolateral ST depression and his troponin I measured 16  𝜇 g/L. The international normalized ratio was 1.1. He was hypotensive with a systolic blood pressure of 95 mmHg and tachycardic with a pulse rate of 120 per minute with low oxygen saturations at 88%. His hemoglobin concentration was measured at 9.0 g/dL.

An urgent computed tomographic pulmonary angiography did not demonstrate fresh pulmonary emboli. Exchange blood transfusion was undertaken because of low oxygen saturations the day after admission but this did not improve the situation. He continued to complain of chest pains and subsequently had an episode of collapse two days later with further T wave and ST ECG changes.

Transthoracic echocardiography (TTE) demonstrated a large thrombus within the right atrium (Figure 1(a)). This was moving freely into the right ventricle, the pulmonary artery, and the inferior vena cava. There was no clinical evidence of deep vein thrombosis.

The patient received thrombolysis with an initial bolus then infusion of alteplase. Repeat TTE 21 hours later demonstrated disappearance of the thrombus (Figure 1(b)). The patient was restarted on warfarin and recovered.

3. Discussion

Spontaneous right atrial thrombus formation is rare in patients without structural right heart disease or atrial fibrillation. Mobile right-sided thrombi, in particular, are thought to be a severe form of venous thromboembolism, arising from deep vein thrombosis [1]. These can produce emboli at any time and are associated with a high mortality rate greater than 40% [2]. Immediate treatment is therefore imperative.

Right heart thrombi have been identified in diseases of hypercoagulability such as protein C and S deficiency [3], Behcets disease [4, 5], and inflammatory bowel disease [6]. It remains a very rare presentation of sickle cell disease but we have found one reported case in literature [7]. In an autopsy case series of fourteen patients with sickle cell disease that died within a 15-year period, right atrial thrombosis was found in one patient who had presented ante mortem with an acute chest syndrome [8].

SCD predisposes to hypercoagulability due to abnormal activation of the fibrinolytic system by abnormal sickle cells which activate the prothrombinase complex resulting in production of high plasma levels of thrombin. Depletion of anticoagulation factors, increased tissue factor expression, and chronic platelet activation also play an important role [9].

Splenectomy in haematological diseases such as Beta thalassaemia intermedia and SCD, have been thought to further contribute to this observed hypercoagulable state and subsequent thromboembolic complications, due to the procoagulant activity of a high number of circulating damaged RBC, thrombocytosis, and activation of the coagulation system which occur [10, 11]. Unlike the Beta thalassaemias however, there is currently little in terms of literature which shows this direct association between sickle cell disease and splenectomy in particular [12].

Up to 30% of patients with SCD will develop pulmonary arterial hypertension (PAH) and this is known to be associated with significant morbidity and mortality. Several mechanisms are recognised in the pathogenesis of PAH which include recurrent hemolysis, nitric oxide deficiency, vascular bed remodeling, and chronic hypoxaemia [13, 14]. Recurrent thromboembolic disease is also thought to contribute and undoubtedly some of such cases can be attributed to occult thromboembolism caused by intracardiac thrombi.

Though SCD is a hypercoaguable state, the roles of anticoagulants have not been well defined and larger controlled trials are required to define their role [9]. As mentioned, chronic pulmonary thromboembolism is a recognized association and in such cases it is generally acceptable to administer oral anticoagulant therapy and there is the suggestion that low dose anticoagulation in these patients may reverse some of the prothrombotic phenomena [15]. Our patient was already on warfarin due to chronic small vessel pulmonary thromboembolism but was Suboptimal from noncompliance issues. Suboptimal anti-coagulation and the risk of intracardiac thrombus formation have already been described in other cases of high-risk patients for intracardiac thrombi formation, such as cardiac surgery [16].

The importance of transthoracic echocardiogram as a key simple, noninvasive, and rapid investigation for diagnosing intracardiac thrombi is highlighted here. A retrospective study by Chartier et al. of 38 patients with mobile right-heart thrombi also underlines the usefulness of TTE as a first-line investigation [1] allowing rapid life-saving treatment to be initiated. Felner et al. in a small study of patients with clinically unsuspected right atrial thrombemboli, found that TTE was instrumental in making a diagnosis and providing information on the size, shape, mobility, and location of subsequently demonstrated intracardiac thrombi in these patients [17]. In more recent studies transoesophageal echocardiogram has been noted to be particularly invaluable in the diagnosis of right-sided cardiac masses and where available may be a preferred option with a high diagnostic yield achievable [18, 19].

There is no clear consensus of the preferred treatment option and until a randomized control trial is embarked on, the debate will continue. Factors that have been considered however include extent, size, shape, and mobility of the cardiac thrombus, preexisting pulmonary embolism/deep vein thrombosis, and cardiopulmonary reserve [3, 20]. Chartier’s study did not delineate a statistical difference between various treatment modalities and mortality; these included surgical thrombectomy, intravenous thrombolysis, intravenous heparin, and percutaneous intervention. However it is worth noting that in the European Cooperative Study, the heparin treated group registered a high mortality rate [1, 21]. In general, patients with intracardiac thrombi who present with coexisting pulmonary embolism and/or hemodynamic embarrassment seem to do better with thrombolytic therapy. This represents a safe and effective option with rapid resolution of thrombus, improvement of hemodynamic status, and echocardiographic parameters of acute right ventricular overload [22]. Complication rates were also noted to be infrequent [23].

Mortality in patients with intracardiac thrombi remains high. Chartier et al. study found that a fifth of their patients diagnosed with right atrial thrombi died within 24 hours off admission [1]. In a review by the European working group of echocardiography, they observed that patients with Type A thrombi (long, thin, extremely mobile thrombi which resembled a worm or a snake), which is similar to what our patient presented with, had early mortality (< or equal to 8 days) in excess of 42% and overall prognosis was generally poor. The presence of pulmonary embolism on its own in association with right heart thromboembolism was found to be a poor prognostic indicator. This further emphasizes the need for rapid diagnosis and emergency treatment to prevent mortality [2].

4. Conclusion

Sickle cell disease as a hypercoaguable state is a rare risk factor for intracardiac thrombus. A high index of suspicion is therefore needed to make a diagnosis. TTE can provide a rapid diagnosis of intracardiac thrombosis and influence immediate life saving management. In this instance, intravenous thrombolytic therapy offered a safer and more acceptable alternative to surgical removal of the thrombus.

References

  1. L. Chartier, J. Béra, M. Delomez et al., “Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients,” Circulation, vol. 99, no. 21, pp. 2779–2783, 1999. View at: Google Scholar
  2. European Working Group on Echocardiography, “The European cooperative study on the clinical significance of right heart thrombi,” European Heart Journal, vol. 10, no. 12, pp. 1046–1059, 1989. View at: Google Scholar
  3. E. Ercan, I. Tengiz, C. Sekuri et al., “Cardiac thrombi in a patient with protein-C and S deficiencies: a case report,” Thrombosis Journal, vol. 2, p. 2, 2004. View at: Publisher Site | Google Scholar
  4. M. Cemri, A. Erkan, M. Ozdemir, and A. Cengel, “Behcet's disease with a large and free right atrial thrombus,” European Journal of Echocardiography, vol. 3, no. 3, pp. 233–235, 2002. View at: Publisher Site | Google Scholar
  5. N. Mogulkoc, M. Burgess, and P. Bishop, “Intracardiac thrombus in Behcet's disease: a systematic review,” Chest, vol. 118, no. 2, pp. 479–487, 2000. View at: Google Scholar
  6. B. Waller, T. Rohr, T. McLaughlin, L. Grider, C. Taliercio, and J. Fetters, “Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review- part V,” Clinical Cardiology, vol. 18, no. 8, pp. 731–734, 1995. View at: Google Scholar
  7. T. Yeghens, S. Benjamin, O. Boyd, C. Pumphrey, and H. Bevan, “Sickle cell anemia, right atrial thrombosis, and the antiphospholipid antibody,” American Journal of Hematology, vol. 50, no. 1, pp. 46–48, 1995. View at: Publisher Site | Google Scholar
  8. A. Gray, E. Anionwu, S. Davies, and M. Brozovic, “Patterns of mortality in sickle cell disease in the United Kingdom,” Journal of Clinical Pathology, vol. 44, no. 6, pp. 459–463, 1991. View at: Google Scholar
  9. K. Ataga and N. Key, “Hypercoagulability in sickle cell disease: new approaches to an old problem,” American Society of Hematology, vol. 1, pp. 91–96, 2007. View at: Google Scholar
  10. C. Cappellini, E. Grespi, E. Cassinerio, D. Bignamini, and G. Fiorelli, “Coagulation and splenectomy: an overview,” Annals of the New York Academy of Sciences, vol. 1054, pp. 317–324, 2005. View at: Publisher Site | Google Scholar
  11. A. Eldor and E. Rachmilewitz, “The hypercoagulable state in thalassemia,” Blood, vol. 99, no. 1, pp. 36–43, 2002. View at: Publisher Site | Google Scholar
  12. K. Ataga, M. Cappellini, and E. Rachmilewitz, “β-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability,” British Journal of Haematology, vol. 139, no. 1, pp. 3–13, 2007. View at: Publisher Site | Google Scholar
  13. R. F. Machado and M. T. Gladwin, “Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective,” Chest, vol. 137, no. 6, pp. 30S–38S, 2010. View at: Publisher Site | Google Scholar
  14. J. Villagra, S. Shiva, L. A. Hunter, R. F. Machado, M. T. Gladwin, and G. J. Kato, “Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin,” Blood, vol. 110, no. 6, pp. 2166–2172, 2007. View at: Publisher Site | Google Scholar
  15. H. J. Wolters, H. T. Cate, L. L. Thomas et al., “Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?” British Journal of Haematology, vol. 90, no. 3, pp. 715–717, 1995. View at: Google Scholar
  16. A. Cheung, S. Levin, S. Weiss, M. Acker, and N. Stenach, “Intracardiac thrombus: a risk of incomplete anticoagulation for cardiac operations,” Annals of Thoracic Surgery, vol. 58, no. 2, pp. 541–542, 1994. View at: Google Scholar
  17. J. Felner, A. Churchwell, and D. Murphy, “Right atrial thromboemboli: clinical, echocardiographic and pathophysiologic manifestations,” Journal of the American College of Cardiology, vol. 4, no. 5, pp. 1041–1051, 1984. View at: Google Scholar
  18. A. Mugge, W. Daniel, A. Haverich, and P. Lichtlen, “Diagnosis of noninfective cardiac mass lesions by two-dimensional echocardiography. Comparison of the transthoracic and transesophageal approaches,” Circulation, vol. 83, no. 1, pp. 70–78, 1991. View at: Google Scholar
  19. A. Z. Schwartzbard, P. A. Tunick, B. P. Rosenzweig, and I. Kronzon, “The role of transesophageal echocardiography in the diagnosis and treatment of right atrial thrombi,” Journal of the American Society of Echocardiography, vol. 12, no. 1, pp. 64–69, 1999. View at: Publisher Site | Google Scholar
  20. G. L. Yung, R. N. Channick, P. F. Fedullo et al., “Successful pulmonary thromboendarterectomy in two patients with sickle cell disease,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1690–1693, 1998. View at: Google Scholar
  21. M. E. Tavel, S. Z. Goldhaber, and K. M. Moser, “Rapidly progressing dyspnea associated with a mass in the right side of the heart,” Chest, vol. 107, no. 3, pp. 866–868, 1995. View at: Google Scholar
  22. F. Greco, G. Bisignani, O. Serafini, D. Guzzo, A. Stingone, and F. Plastina, “Successful treatment of right heart thromboemboli with IV recombinant tissue-type plasminogen activator during continuous echocardiographic monitoring: a case series report,” Chest, vol. 116, no. 1, pp. 78–82, 1999. View at: Publisher Site | Google Scholar
  23. D. S. Kanter, K. M. Mikkola, S. R. Patel, J. A. Parker, and S. Z. Goldhaber, “Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors,” Chest, vol. 111, no. 5, pp. 1241–1245, 1997. View at: Google Scholar

Copyright © 2011 H. O. Savage et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

763 Views | 460 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.